Prices correct at time of publication. A hard-working pair of sandals is a must-have for summer. Whether you’re heading to the beach or strolling around the city, a good-quality pair that supports ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

In the 14-week phase 2b study by Sanofi and Teva's U.S. affiliate held in the U.S., Europe and Israel, the drug, called duvakitug, showed that 36.2% of low dose and 47.8% of high dose patients ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Merck is working on the monoclonal antibody MK-7240—formerly known as PRA023—which it acquired in its $10.8 billion buyout of Prometheus Biosciences last year. In phase 2 results disclosed in ...

Duvakitug isn't just another drug in Teva's pipelineit's the drug. With consistent efficacy across patient groups and no major safety hiccups, this TL1A antibody therapy is now a frontrunner in ...